Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System

MINNEAPOLIS, July 13 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex:
UPI), a medical device company that develops, manufactures and markets
innovative proprietary products for the treatment of voiding dysfunctions,
announced today the issuance of United States Patent No. 7,536,226 entitled,
"Electro-Nerve Stimulator System and Methods." The patent covers the company's
Urgent(R) PC system and stimulation methods for treatment of the overactive
bladder ("OAB") symptoms of urinary urgency, urge incontinence and frequency
of urinary voids.

The Urgent PC Neuromodulation System is a minimally invasive, office-based,
nonsurgical system designed to deliver retrograde access to the sacral plexus
through percutaneous electrical stimulation of the posterior tibial nerve. The
Urgent PC system combines a pulse generator and a lead set to transfer
electrical current from the pulse generator to the posterior tibial nerve, and
includes a single use feature to prevent reuse of the lead set. By preventing
reuse of lead sets, the Urgent PC System eliminates the health risks otherwise
associated with re-using the same electrodes.

"We are very pleased that the United States Patent Office has awarded this
patent on the unique features of our stimulation systems and methods," said
David Kaysen, President and CEO. "This newly issued patent underscores our
commitment to protect the unique features of the Urgent PC system. The
system's ease of use and treatment effectiveness, coupled with a minimally
invasive procedure and single-use features, are seen as key positives by our
many clinical users as well as patients treated for the symptoms of OAB."

About the Urgent PC Neuromodulation System

The Urgent PC neuromodulation system is a proprietary, minimally invasive
nerve stimulation device designed for office-based treatment of urge
incontinence, urinary urgency and urinary frequency, symptoms often associated
with overactive bladder. Application of neuromodulation therapy targets
specific nerve tissue and disrupts the signals that lead to these symptoms.

Uroplasty sells the Urgent PC system in the United States, Canada, and
countries recognizing the CE mark. Outside of the United States, Urgent PC is
also indicated for the treatment of fecal incontinence.

For more information about the Urgent PC Neuromodulation System, please call
866-277-0466 or visit www.uroplasty.com.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned
subsidiaries in The Netherlands and the United Kingdom, is a medical device
company that develops, manufactures and markets innovative proprietary
products for the treatment of voiding dysfunctions. Our focus is the continued
commercialization of our Urgent PC system, which we believe is the only
FDA-approved minimally invasive nerve stimulation device designed for
office-based treatment of urinary urgency, urinary frequency and urge
incontinence - symptoms often associated with overactive bladder.

We also offer Macroplastique(R) Implants, an injectable urethral bulking agent
for the treatment of adult female stress urinary incontinence primarily due to
intrinsic sphincter deficiency. For more information on the company and its
products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information
This press release contains forward-looking statements, which reflect our best
estimates regarding future events and financial performance. Forward-looking
statements include statements about the scope of coverage and potential
applications for Uroplasty's patents, whether Uroplasty's issued patents will
be challenged and whether such challenges will have an adverse effect on the
scope of the patents; whether Uroplasty will pursue enforcement of its issued
patents or be successful in any such enforcement efforts; whether Uroplasty
will successfully prosecute additional patent applications and if so, whether
such applications will lead to the issuance of additional patents. These
forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially from our anticipated results. We
discuss in detail the factors that may effect the achievement of our
forward-looking statements in our Annual Report on Form 10-K filed with the
SEC.

For Further Information:

Uroplasty, Inc. EVC Group
--------------- ---------
David Kaysen, President and CEO, or Doug Sherk (Investors)
Medi Jiwani, Vice President, CFO, and 415.896.6820
Treasurer,
952.426.6140 Chris Gale (Media)
646.201.5431

SOURCE Uroplasty, Inc.

David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, and
Treasurer, +1-952-426-6140, both of Uroplasty, Inc.; or Investors, Doug Sherk,
+1-415-896-6820, or media, Chris Gale, +1-646-201-5431, both of EVC Group, for
Uroplasty, Inc.